The Globe and Mail reported on Friday, May 12, edition that while Scotia Capital analyst Michael Doumet is sticking with his "sector outperform" call for Savaria. The Globe's David Leeder writes in the Eye On Equities column that Mr. Doumet tweaked his share target ahead by 50 cents to $20.50. Mr. Doumet says in a note: "1Q EBITDA was 5 per cent ahead of the Street, with sales strength (healthy demand, easing supply chains, higher prices, and execution of synergies) driving the beat. Patient care EBITDA margins climbed more than 700bp -- shedding light on the margin potential for the segment (i.e. 20 per cent), but were offset by softer accessibility margins. Overall, we liked the quarter and believe it provides positive read-throughs (i.e. the unchanged 2023 EBITDA guide and the Norwegian auto divestiture implies 2-per-cent to 3-per-cent increase). SIS is viewed as a solid organic grower. Given the recent trends, we think margin story is as good. Supply chain bottlenecks, inflationary pressures, and lagging price increases pressured margins for 12 to18 months. Consolidated margins appear to be moving upward now. Demand weakness in housing and/or Europe did not materialize to the extent investors feared."